Literature DB >> 2235119

Early changes in the permeability of the blood-brain barrier produced by toxins associated with liver failure.

H J McClung1, H R Sloan, P Powers, A J Merola, R Murray, B Kerzner, J D Pollack.   

Abstract

Our study was designed to determine whether substances that appear in the serum during the course of liver failure have a detrimental effect on the passive permeability of the blood-brain [blood-cerebrospinal fluid (CSF)] barrier. Lactic acid, octanoic acid, and ammonia were infused into rabbits for 4 h. The permeability changes of the blood-brain barrier were quantified by infusing polyethylene glycol 400 (PEG 400) and measuring the quantity and average mol wt of the PEG 400 that entered the CSF. The lipid solubility and effective diffusional radius of the PEG molecules were also quantified to provide greater precision for measurements using this probe. None of the animals receiving toxic infusions became seriously ill during the infusions. Low dose infusions of lactic acid, octanoic acid, and ammonia increased the effective pore diameter of the blood-brain barrier from 7.3 A to an average of 8.5 A. The amount of PEG entering the CSF increased from 1.7 to 4.0 (p less than 0.025), 4.7 (p less than 0.025), and 6.7 (p less than 0.001) mmol/L, respectively. Rabbits with galactosamine-induced liver failure had 10.1 mmol/L PEG 400 in the CSF (P less than 0.001) before any evidence of cerebral edema. These changes occur soon after these toxins accumulate in the plasma and may alone or together with other toxins account for the permeability changes that allow neurotoxic substances to enter the brain during hepatic disease and encephalopathies such as Reye's syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2235119     DOI: 10.1203/00006450-199009000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity.

Authors:  Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

2.  Bridging to transplantation in acute liver failure in a 7-month-old infant.

Authors:  Gerhard Trittenwein; Harald Boigner; Gehan Mostafa; Gudrun Burda; Adolf Mühl; Gabriele Amann; Arnold Pollak
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain.

Authors:  Meiqing Shi; Shu Shun Li; Chunfu Zheng; Gareth J Jones; Kwang Sik Kim; Hong Zhou; Paul Kubes; Christopher H Mody
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

4.  Unusual cyclosporin related neurological complications in recipients of liver transplants.

Authors:  M R Cilio; O Danhaive; J F Gadisseux; J B Otte; E M Sokal
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

5.  Integration of PEG 400 into a self-nanoemulsifying drug delivery system improves drug loading capacity and nasal mucosa permeability and prolongs the survival of rats with malignant brain tumors.

Authors:  Yu-Shuan Chen; Yu-Han Chiu; Yuan-Sheng Li; En-Yi Lin; Dean-Kuo Hsieh; Chia-Hung Lee; Mao-Hsuan Huang; Hong-Meng Chuang; Shinn-Zong Lin; Horng-Jyh Harn; Tzyy-Wen Chiou
Journal:  Int J Nanomedicine       Date:  2019-05-16

6.  Secondary Dysfunction of the Intestinal Barrier in the Pathogenesis of Complications of Acute Poisoning.

Authors:  Ju Ju Ivnitsky; T V Schäfer; V L Rejniuk; O A Vakunenkova
Journal:  J Evol Biochem Physiol       Date:  2022-08-28       Impact factor: 1.621

7.  Cell Therapy for Acute Liver Failure - Ideal source of cell.

Authors:  A A Khan; N Parveen; M A Habeeb; S Paspala; A Rajendraprasad; S Mahaboob Vali; Mn Khaja; N Lakshmi; R Pramila; Cm Habibullah
Journal:  J Stem Cells Regen Med       Date:  2008-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.